Next Article in Journal
Long-Term and Quality of Survival in Patients Treated for Acute Lymphoblastic Leukemia during the Pediatric Age
Previous Article in Journal
The Effect of Tetrastarch Solution for Capillary Leak Syndrome Following Allogeneic Hematopoietic Stem Cell Transplantation: A Report of 2 Cases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Hematology Reports
Volume 13
Issue 1
10.4081/hr.2021.8780
hematolrep-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Hematology Reports is published by MDPI from Volume 14 Issue 1 (2022). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with PAGEPress.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Brief Report

Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach

by
Panayotis Kaloyannidis
1,*,
Eshrak Al Shaibani
1,
Asif Moinnudin
2,
Khalid Al Anezi
1 and
Hani Al Hashmi
1
1
Department of Adult Hematology and Stem Cell Transplantation, King Fahad Specialist Hospital, Ammar Bin Thabit St., Al Muraikabat, Dammam 314444, Saudi Arabia
2
Department of Medical Imaging, King Fahad Specialist Hospital, Dammam 314444, Saudi Arabia
*
Author to whom correspondence should be addressed.
Hematol. Rep. 2021, 13(1), 8780; https://doi.org/10.4081/hr.2021.8780
Submission received: 6 July 2020 / Revised: 2 January 2021 / Accepted: 1 February 2021 / Published: 5 March 2021

Abstract

For patients with Hodgkin Lymphoma (HL) who experience relapse post allogeneic stem cell transplantation, limited treatment options exist, and the ultimate outcome is poor. Recently, the programmed cell death protein-1 (PD-1) inhibitors have shown remarkable efficacy in patients with refractory/relapsed HL, also demonstrating an acceptable safety profile. However, due to effects on T-cell activity, the use of PD-1 inhibitors post allografting may potentially increase the risk of treatment-emergent graft versus host disease. We herein report the clinical course of a patient who experienced multiple relapses of HL post allogeneic stem cell transplantation. He failed several treatment modalities but he responded to escalating doses of the PD-1 inhibitor nivolumab, given at two different treatment time points, also demonstrating minimal and easily manageable toxicity.
Keywords: allogeneic hematopoietic stem cell transplantation; hodgkin lymphoma; programmed death-1 (PD-1) inhibitors allogeneic hematopoietic stem cell transplantation; hodgkin lymphoma; programmed death-1 (PD-1) inhibitors

Share and Cite

MDPI and ACS Style

Kaloyannidis, P.; Al Shaibani, E.; Moinnudin, A.; Al Anezi, K.; Al Hashmi, H. Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach. Hematol. Rep. 2021, 13, 8780. https://doi.org/10.4081/hr.2021.8780

AMA Style

Kaloyannidis P, Al Shaibani E, Moinnudin A, Al Anezi K, Al Hashmi H. Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach. Hematology Reports. 2021; 13(1):8780. https://doi.org/10.4081/hr.2021.8780

Chicago/Turabian Style

Kaloyannidis, Panayotis, Eshrak Al Shaibani, Asif Moinnudin, Khalid Al Anezi, and Hani Al Hashmi. 2021. "Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach" Hematology Reports 13, no. 1: 8780. https://doi.org/10.4081/hr.2021.8780

APA Style

Kaloyannidis, P., Al Shaibani, E., Moinnudin, A., Al Anezi, K., & Al Hashmi, H. (2021). Repeated Courses of Escalating Doses of Nivolumab in Refractory Hodgkin Lymphoma with Recurrent Relapses Post Allografting: A Safe and Effective Treatment Approach. Hematology Reports, 13(1), 8780. https://doi.org/10.4081/hr.2021.8780

Article Metrics

Back to TopTop